The strongest version of this narrative positions BIO-Europe Spring 2026 as a pivotal moment for European biotech, showcasing resilience amid funding challenges and geopolitical instability. The event’s emphasis on partnerships and innovation—from neurodegeneration to AI-driven drug discovery—paints Europe as a rising hub, particularly for underrepresented regions like Portugal. However, the optimism is tempered by structural inequities: Southern Europe remains underfunded, women’s health and ra...